NJ Esketamine Nasal Spray Treatment For Depression With BlueShield Insurance

Oct 2, 2023

Esketamine therapy is a groundbreaking new approach to mental health treatment and New Jersey-based Relevance Behavioral Health (+1-866-245-1497) now offers the treatment as part of its integrative plans. Adults with treatment-resistant depression and major depressive disorder can be vulnerable to addiction and other issues.

Relevance Behavioral Health now offers the FDA-approved Spravato® nasal spray as part of its multidisciplinary treatment programs for Mental Health and depressive disorders.

Treatment-resistant depression is a complex and challenging condition that requires a personalized approach and close monitoring by a mental health professional. By combining treatments such as ketamine and clinical therapy, a person can finally free themselves of their debilitating mental health challenges. The beauty of ketamine is that it acts much more quickly than traditional antidepressants, so you can focus your efforts on recovery.

Go to https://relevancerecovery.com/ for more information.

Relevance Behavioral Health accepts almost all health insurance providers, including Blue Cross Blue Shield, Cigna, and Aetna. Esketamine has shown significant promise in the treatment of major depression and was approved for such use by the US Foods and Drug Administration (FDA) over four years ago.

While traditional antidepressants, such as SSRIs and SNRIs, can take several weeks to take full effect, a recent report from Harvard Medical School points out that you can start to feel improvements in as little as 40 minutes when you receive esketamine. This is particularly beneficial when seeking to address secondary problems, such as substance abuse and addiction.

For those reasons, Relevance Behavioral Health is now offering esketamine to assist with a range of mental health challenges, including depression, anxiety, ADD/ADHD, PTSD, bipolar disorder, and co-occurring disorders. The treatments can form part of a personalized multidisciplinary plan, with the overall goal of providing long-term recovery.

Many individuals who deal with mental health issues have had trouble finding medication that works for them. Some examples of drugs that adults with treatment-resistant depression (TRD) have tried and failed to use are:

   •Selective serotonin reuptake inhibitors (SSRIs), such as fluoxetine (Prozac), sertraline (Zoloft), and escitalopram (Lexapro)

   •Serotonin-norepinephrine reuptake inhibitors (SNRIs), such as venlafaxine (Effexor) and duloxetine (Cymbalta)

   •Atypical antidepressants, such as bupropion (Wellbutrin) and mirtazapine (Remeron)

   •Tricyclic antidepressants (TCAs), such as amitriptyline (Elavil) and nortriptyline (Pamelor)

   •Monoamine oxidase inhibitors (MAOIs), such as phenelzine (Nardil) and tranylcypromine (Parnate)

   •Lithium (Eskalith, Lithobid), a mood stabilizer that can enhance the effects of antidepressants

   •Antipsychotic medications, such as olanzapine (Zyprexa) and quetiapine (Seroquel), which can be used as augmentation strategies in combination with antidepressants.

“Spravato treatment offers a new opportunity for those who have found limited success from other options,” a company representative explained. “At Relevance Recovery, our team of clinical professionals can administer appropriate doses of Spravato to help clients achieve their treatment goals. Many who use Spravato experience almost instant changes to their mood, outlook, and energy levels, all of which can make it far easier to navigate the trickier parts of recovery.”

Spravato® is also known to help individuals struggling with addiction. Ketamine may help individuals with addiction issues by modulating glutamate levels in the brain. Glutamate is an important neurotransmitter that is involved in learning, memory, and the reward system of the brain. It is believed that disrupting glutamate signaling can help to reduce cravings and restore balance to the brain's reward system, which may be disrupted in addiction. Preclinical and clinical trials have shown that ketamine, the racemic mixture of Spravato (including esketamine), may have the potential to treat substance-related disorders, including alcohol use disorder, opioid dependence, and cocaine use disorder. However, the evidence is still limited, and further research is needed to establish the safety and efficacy of these treatments.

About Relevance Behavioral Health

Located in Freehold, New Jersey, Relevance Behavioral Health offers a range of mental health and substance abuse treatment programs, including detoxification, inpatient, partial day, intensive outpatient, and aftercare. The center takes a multifaceted approach to treatment, with plans being developed around the circumstances of each client.

“Relevance Behavioral Health saved my life,” one client recently stated. “Anyone struggling with mental health or addiction would 100% benefit from coming here. This place taught me so many skills and coping mechanisms I’ve never even heard of before, all of which helped me recover.”

For innovative and science-based treatment, contact the award-winning team at Relevance Behavioral Health.

Check out https://relevancerecovery.com/ so you can learn more.


Web Analytics